We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly's Emgality Gets FDA Priority Review for Cluster Headache
Read MoreHide Full Article
Eli Lilly and Company (LLY - Free Report) announced that the FDA has granted a priority review to the supplemental biologics license application (sBLA) for its calcitonin gene-related peptide (CGRP) antibody, Emgality (galcanezumab). With this latest sBLA filing, Lilly is looking to get Emgality injection approved for the preventive treatment of episodic cluster headache in adult patients.
Notably, Lilly gained an FDA approval for Emgality, its CGRP antibody, for adult migraine in late last September.
Generally, the FDA provides a priority review designation to drugs with potential for driving significant improvements in the safety and effectiveness of treatment, prevention or diagnosis of a serious disease.
The sBLA filing was based on data from a phase III study, which evaluated the safety and efficacy of Emgality injection (300mg) in adult patients with episodic cluster headache. Last September, the FDA granted a Breakthrough Therapy status to Emgality for the same indication. Currently, there are no approved medicines in the United States for treating episodic cluster headache. Thus, a nod will help Lilly gain access to a broader patient population and boost sales for this promising drug.
Shares of Lilly have rallied 11% so far this year compared with the industry’s increase of 3.3%.
Emgality was the third CGRP antibody to get an FDA nod in 2018 for migraine treatment. Amgen’s (AMGN - Free Report) and Novartis’ CGRP antibody, Aimovig, was approved and launched in the United States during the second quarter of 2018 while Teva’s (TEVA - Free Report) Ajovy was also approved last September.
Lilly is also enrolling patients in phase III studies on Emgality for the preventive treatment of migraine in children and adolescents, aged 6-17 years.
Notably, Lilly’s overall pain portfolio looks promising. Apart from Emgality, the company is developing lasmiditan, which is currently under review in the United States for the treatment of acute migraine in adult patients. Lilly along with partner Pfizer (PFE - Free Report) is developing tanezumab, which is being evaluated in several phase III programs for treating osteoarthritis pain (OA), chronic low back pain and cancer pain in adult patients.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Lilly's Emgality Gets FDA Priority Review for Cluster Headache
Eli Lilly and Company (LLY - Free Report) announced that the FDA has granted a priority review to the supplemental biologics license application (sBLA) for its calcitonin gene-related peptide (CGRP) antibody, Emgality (galcanezumab). With this latest sBLA filing, Lilly is looking to get Emgality injection approved for the preventive treatment of episodic cluster headache in adult patients.
Notably, Lilly gained an FDA approval for Emgality, its CGRP antibody, for adult migraine in late last September.
Generally, the FDA provides a priority review designation to drugs with potential for driving significant improvements in the safety and effectiveness of treatment, prevention or diagnosis of a serious disease.
The sBLA filing was based on data from a phase III study, which evaluated the safety and efficacy of Emgality injection (300mg) in adult patients with episodic cluster headache. Last September, the FDA granted a Breakthrough Therapy status to Emgality for the same indication. Currently, there are no approved medicines in the United States for treating episodic cluster headache. Thus, a nod will help Lilly gain access to a broader patient population and boost sales for this promising drug.
Shares of Lilly have rallied 11% so far this year compared with the industry’s increase of 3.3%.
Emgality was the third CGRP antibody to get an FDA nod in 2018 for migraine treatment. Amgen’s (AMGN - Free Report) and Novartis’ CGRP antibody, Aimovig, was approved and launched in the United States during the second quarter of 2018 while Teva’s (TEVA - Free Report) Ajovy was also approved last September.
Lilly is also enrolling patients in phase III studies on Emgality for the preventive treatment of migraine in children and adolescents, aged 6-17 years.
Notably, Lilly’s overall pain portfolio looks promising. Apart from Emgality, the company is developing lasmiditan, which is currently under review in the United States for the treatment of acute migraine in adult patients. Lilly along with partner Pfizer (PFE - Free Report) is developing tanezumab, which is being evaluated in several phase III programs for treating osteoarthritis pain (OA), chronic low back pain and cancer pain in adult patients.
Zacks Rank
Lilly currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>